The myelodysplastic syndromes (MDS) are clonal disorders of haematopoiesis. Clinical presentation and morphologic findings are heterogeneous, making the diagnosis often difficult, especially in the early stages. Recently, refined definitions and standards in the diagnosis and treatment of MDS have been proposed, but a number of questions remain open. The objective of this research topic is to bring together the scientific community to extend the current level of knowledge in the MDS field with manuscripts encompassing recent advances concerning the defaults of maturation pathways in haematopoietic cells, microenvironment and immune-related deficiencies including antigen processing and presentation abnormalities, metabolic disturbances, genomic and post-transcriptional disorders. All this knowledge will be useful in the development of biological tests for accurately diagnosing of MDS and highlights new perspectives on the identification of therapeutic targets.
The myelodysplastic syndromes (MDS) are clonal disorders of haematopoiesis. Clinical presentation and morphologic findings are heterogeneous, making the diagnosis often difficult, especially in the early stages. Recently, refined definitions and standards in the diagnosis and treatment of MDS have been proposed, but a number of questions remain open. The objective of this research topic is to bring together the scientific community to extend the current level of knowledge in the MDS field with manuscripts encompassing recent advances concerning the defaults of maturation pathways in haematopoietic cells, microenvironment and immune-related deficiencies including antigen processing and presentation abnormalities, metabolic disturbances, genomic and post-transcriptional disorders. All this knowledge will be useful in the development of biological tests for accurately diagnosing of MDS and highlights new perspectives on the identification of therapeutic targets.
